

GI MAP Test Launches Cyclospora Guidance Service for Customers With a Detected Test Result

GI MAP Test, has launched a guidance resource for customers whose test result detects the intestinal parasite Cyclospora.

ST AUGUSTINE, FL, UNITED STATES, August 24, 2026 /EINPresswire.com/ -- [GI MAP Test](#), a service that provides access to the [GI-MAP™](#) comprehensive stool test in the United States and Canada, has launched a guidance resource for customers whose test result detects the intestinal parasite [Cyclospora](#). The company announced the service on August 5, 2026.



The resource is provided at no additional cost to eligible customers. It is sent by email together with the customer's test results, and only when the result detects Cyclospora. It is not sent at the time the test is purchased.

What the Service Provides

The guidance resource is educational. It was written to answer the practical questions a person may have in the days immediately after a parasite is detected in a stool test.

The resource explains what Cyclospora is and what a detected result on the panel may mean. It describes common sources of contamination so customers can reduce the risk of a repeat exposure. It also identifies symptoms that may require urgent medical attention rather than waiting for a routine appointment, and it sets general expectations for digestive recovery, including why symptoms can continue for a period after an infection has been treated.

The company states clearly what the resource does not do. It does not provide prescription medication instructions or dosing. It does not diagnose a condition, interpret symptoms in place of a medical evaluation, or offer any self-treatment pathway. Customers are directed to a

licensed clinician for evaluation and treatment.

"A laboratory result is only useful if the person holding it knows what to do next," said Madison Ordway, FDN-P, the Functional Diagnostic Nutrition Practitioner who reviews the company's educational content. "The purpose of this resource is to help people arrive at their appointment prepared, and to explain why recovery can take time even after treatment is complete. It is not a replacement for a prescriber."

How the Test Detects the Parasite

The GI-MAP™ is an at-home stool test analyzed by Diagnostic Solutions Laboratory, a CLIA-certified laboratory in the United States. It uses quantitative real-time PCR (qPCR) DNA analysis to detect and measure more than 85 gut targets from a single sample. These include bacterial, parasitic and viral pathogens, fungi and yeast, commensal bacteria, and markers of digestion, inflammation and immune function.

Cyclospora is included in the protozoan parasite section of the panel. Because qPCR identifies specific DNA sequences rather than relying on culture or microscopy, it can detect organisms that are present in small numbers. Results are returned in approximately 14 to 16 days after the laboratory receives the sample and are reviewed by a practitioner.

Why the Company Created the Service

Public health authorities, including the U.S. Centers for Disease Control and Prevention, describe Cyclospora as a microscopic single-celled parasite that infects the lining of the small intestine. People become infected by consuming contaminated food or water. Its symptoms, including watery diarrhea, loss of appetite, and fatigue, resemble many other digestive infections, so laboratory testing is needed to identify the organism, and treatment requires prescription therapy ordered by a qualified clinician.

According to the company, that combination is what created the need for the service. A customer can receive a detected result at home, without a clinician present to explain it, and then face a wait before an appointment. The resource is intended to fill that gap with plain-language information and to make the eventual appointment more productive.

Who Is Eligible

The guidance resource is available to customers who ordered their GI-MAP™ test through GI MAP Test and received a result detecting Cyclospora. It is included as part of the service, and there is nothing further to purchase.

Customers who ordered their test through another practitioner, clinic, distributor or laboratory are not covered by the service and are advised to return to the provider who placed their order.

The company also advises anyone who is acutely unwell not to wait for the resource, and to contact a clinician or seek urgent medical care.

Due to state laboratory regulations, the GI-MAP™ test cannot be processed for residents of New York, New Jersey, or Rhode Island.

The announcement and further information are available at

<https://gimaptest.com/en/cyclospora/>

Madison Ordway, FDN-P

Real Health Diagnostics Inc.

+1 672-969-1200

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/935478982>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.